UNCY
NASDAQ HealthcareUnicycive Therapeutics, Inc. - Common Stock
Biotechnology
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
๐ Market Data
| Price | $5.05 |
|---|---|
| Volume | 852,019 |
| Market Cap | 138.33M |
| Beta | 1.790 |
| RSI (14-Day) | 26.9 Oversold |
| 200-Day MA | $6.33 |
| 50-Day MA | $7.04 |
| 52-Week High | $8.74 |
| 52-Week Low | $3.71 |
| Forward P/E | 0.98 |
| Price / Book | 3.38 |
๐ฏ Investment Strategy Scores
UNCY scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (94/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find UNCY in your text
Paste any article, transcript, or post โ the tool will extract UNCY and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.